HER2-targeted therapies
Oncologyยท 8 reviewed drugsยท 14311 cited findings behind them
What the regulatory reviews cover
This library includes several HER2-targeted therapies that have undergone regulatory review. These drugs are indicated for various HER2-positive cancers, including breast cancer, non-small cell lung cancer, solid tumors, and biliary tract cancer. The indications range from early-stage and locally advanced disease to metastatic and unresectable conditions, often in patients who have received prior treatments.
Regulatory review documents report a variety of outcomes for these therapies. For example, Enhertu demonstrated an Objective response rate (ORR) of 60.3% in its review. Perjeta showed a PFS Hazard Ratio of 0.62, indicating an improvement in progression-free survival. Tukysa's review noted an OS Hazard Ratio of 0.68. Kadcyla's review reported a Median Progression-free survival of 14.2. It is important to note that these figures are derived from different trials and are not directly comparable head-to-head.
The drugs โ one cited result each
| Enhertu Daiichi Sankyo Company, Limited | Objective response rate (ORR): 60.3 Daiichi Sankyo Company, Limited โ Enhertu FDA Review (BLA761, p.18 |
| Perjeta Roche Holding AG | PFS Hazard Ratio: 0.62 Roche Holding AG โ Perjeta EMA EPAR public assessment report, p.3 |
| Tukysa Pfizer Inc. | OS Hazard Ratio: 0.68 Pfizer Inc. โ Tukysa FDA Review, p.24 |
| Kadcyla Roche Holding AG | Median Progression-free survival: 14.2 Roche Holding AG โ Kadcyla EMA EPAR public assessment report, p.74 |
| Phesgo Roche Holding AG | OS improvement with pertuzumab in MBC (CLEOPATRA trial): 16 Roche Holding AG โ Phesgo EMA EPAR public assessment report, p.14 |
| Herceptin Roche Holding AG | patients with Ctrough > 20 ฮผg/mL at pre-dose Cycle 8 (IV arm): 98.7 Roche Holding AG โ Herceptin EMA EPAR variation assessment r, p.35 |
| Ziihera Jazz | Confirmed ORR in Total population: 37.9 Jazz โ Ziihera EMA EPAR public assessment report (EMEA/H/C/0, p.130 |
| Tuznue Prestige Biopharma | Ratio of geometric mean of AUC0-inf (HD201 vs. EU-Herceptin): 102.45 % Prestige Biopharma โ Tuznue EMA EPAR public assessment repor, p.38 |
Different drugs were studied in different trials โ these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs โ searchable, comparable and answerable in plain language โ is in the Oncology research library โ
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only โ not medical or investment advice.